Literature DB >> 9146619

Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing.

G L Lu-Yao1, M Friedman, S L Yao.   

Abstract

PURPOSE: We monitored the use of radical prostatectomy in medicare beneficiaries before and after the introduction of prostate specific antigen (PSA) testing.
MATERIALS AND METHODS: Radical prostatectomies performed on medicare beneficiaries between 1984 and 1995 were identified through the medicare claims data base. Medicare enrollment files were used to define the population at risk and age-adjusted rates were standardized to the 1990 United States medicare population.
RESULTS: Rates of radical prostatectomy have steadily increased since 1984. A sharp increase in radical prostatectomy rates followed the institution of PSA testing after which a prominent decrease, particularly among older age groups, was evident. During the peak year of 1992 the age-adjusted rates of radical prostatectomy for white and black men 65 to 79 years old in the United States were 461.2 and 294.5/100,000 men. Between 1992 and 1995 the rates of radical prostatectomy among white men decreased by 22, 47 and 69% for patients 65 to 69, 70 to 74 and 75 to 79 years old, respectively. The corresponding changes among black men were +6, -18 and -47%, respectively. Differences in the age-adjusted rates between white and black men have narrowed in recent years, ranging from 166.7 (1992) to 29.7 (1995)/100,000 men.
CONCLUSIONS: Recent years have been marked by a rapid increase in the use of radical prostatectomy, which peaked in 1992. Subsequent to 1992 a sharp decrease occurred, which was particularly evident in older and white men. Racial differences in the use of radical prostatectomy have narrowed in recent years.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146619

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Prostate-specific antigen testing among the elderly in community-based family medicine practices.

Authors:  Shawna V Hudson; Pamela Ohman-Strickland; Jeanne M Ferrante; Grace Lu-Yao; A John Orzano; Benjamin F Crabtree
Journal:  J Am Board Fam Med       Date:  2009 May-Jun       Impact factor: 2.657

2.  Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Authors:  Richard M Hoffman; Linda C Harlan; Carrie N Klabunde; Frank D Gilliland; Robert A Stephenson; William C Hunt; Arnold L Potosky
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

3.  Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.

Authors:  Paul G Corn; Timothy C Thompson
Journal:  Cancer Manag Res       Date:  2010-05-10       Impact factor: 3.989

4.  Salvage radiotherapy after radical prostatectomy: outcomes and prognostic factors especially focusing on pathological findings.

Authors:  Satoko Hayashi; Keiji Hayashi; Ryo-ichi Yoshimura; Hitoshi Masuda; Kazunori Kihara; Hitoshi Shibuya
Journal:  J Radiat Res       Date:  2012-07-10       Impact factor: 2.724

5.  Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA.

Authors:  Richard M Hoffman; S Noell Stone; David Espey; Arnold L Potosky
Journal:  BMC Cancer       Date:  2005-03-08       Impact factor: 4.430

Review 6.  Update on Screening for Urological Malignancies.

Authors:  Azik Hoffman; Elizabeth E Half
Journal:  Rambam Maimonides Med J       Date:  2017-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.